指南
ANCA相关性血管炎
医学
血管炎
肾病科
肾脏疾病
重症监护医学
免疫学
内科学
病理
疾病
作者
Jürgen Floege,David Jayne,Jan‐Stephan Sanders,Vladimír Tesař,Ethan M Balk,Craig E. Gordon,Gaelen P. Adam,Marcello Tonelli,Michael Cheung,Amy Earley,Brad H. Rovin
标识
DOI:10.1016/j.kint.2023.10.009
摘要
In 2021, the Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases was published. KDIGO is committed to providing the nephrology community with periodic updates, based on new developments for each disease. For patients with anti-neutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV), avacopan received regulatory approval in late 2021, leading to this KDIGO guideline update. In addition, the evidence supporting a lower-dose glucocorticoid induction regimen or even complete replacement of glucocorticoids has become stronger. Herein, an executive summary of the most important guideline changes from the AAV chapter is provided as a quick reference.
科研通智能强力驱动
Strongly Powered by AbleSci AI